Drug Profile
Melanoma vaccine - Ichor Medical Systems/Memorial Sloan-Kettering Cancer Center
Alternative Names: Mouse tyrosinase plasmid DNA vaccine; pINGmuTyr; Xenogeneic tyrosinase DNA vaccineLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Ichor Medical Systems; Memorial Sloan-Kettering Cancer Center
- Class Cancer vaccines; DNA vaccines; Gene therapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Malignant melanoma
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Malignant-melanoma in USA (IM, Injection)
- 05 Mar 2008 Ichor initiates enrolment in the final and highest dose level of its phase I trial for melanoma in the US
- 15 May 2007 Phase-I clinical trials in Malignant melanoma in USA (IM)